title: The revised IPSS is a powerful tool to evaluate the outcome of MDS patients treated with azacitidine: the GFM experience.
authors.forename: Mathilde
authors.initials: M
authors.lastname: Lamarque
authors.forename: Sophie
authors.initials: S
authors.lastname: Raynaud
authors.forename: Raphael
authors.initials: R
authors.lastname: Itzykson
authors.forename: Sylvain
authors.initials: S
authors.lastname: Thepot
authors.forename: Bruno
authors.initials: B
authors.lastname: Quesnel
authors.forename: Francois
authors.initials: F
authors.lastname: Dreyfus
authors.forename: Odile Beyne
authors.initials: OB
authors.lastname: Rauzy
authors.forename: Pascal
authors.initials: P
authors.lastname: Turlure
authors.forename: Norbert
authors.initials: N
authors.lastname: Vey
authors.forename: Christian
authors.initials: C
authors.lastname: Recher
authors.forename: Caroline
authors.initials: C
authors.lastname: Dartigeas
authors.forename: Laurence
authors.initials: L
authors.lastname: Legros
authors.forename: Jacques
authors.initials: J
authors.lastname: Delaunay
authors.forename: Sorin
authors.initials: S
authors.lastname: Visanica
authors.forename: Aspasia
authors.initials: A
authors.lastname: Stamatoullas
authors.forename: Pierre
authors.initials: P
authors.lastname: Fenaux
authors.forename: Lionel
authors.initials: L
authors.lastname: Adès
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use*; D001374:Azacitidine / Q000627:therapeutic use*; D001772:Blood Cell Count; D020732:Cytogenetic Analysis; D005500:Follow-Up Studies; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine